Rydar Equities’s Regeneron Pharmaceuticals REGN Stock Holding History

Rydar Equities’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$14.8K	Buy	+20	New	+$15.1K	0.01%	278

Other funds holding REGN

GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

PensionDanmark Copenhagen O, Denmark $12.3B AUM 33.99% 1-Year Est. Return

Rydar Equities's REGN Position: Q3 2026 in Review

Rydar Equities opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2026: 20 shares worth $14.8K. The stake represents 0.01% of the portfolio and ranks #278 among its holdings.

207 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

Rydar Equities held 20 shares of Regeneron Pharmaceuticals worth $14.8K as of Q3 2026.
Regeneron Pharmaceuticals was a new Rydar Equities position in Q3 2026.
Regeneron Pharmaceuticals made up 0.01% of Rydar Equities's portfolio in Q3 2026, its #278 holding.
207 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Rydar Equities's 13F filing for Q3 2026, filed 13 Oct 2026.